CASPorter: A Novel Inducible Human CASP1/NALP3/ASC Inflammasome Biosensor

References

• Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol. 1995;17(1):1–12. doi:10.1097/00043426-199502000-00001
   PubMed Web of Science ®Google Scholar
• Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535–1548. doi:10.1056/NEJMra023001
   PubMed Web of Science ®Google Scholar
• Pui C-H, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185–196. doi:10.1053/j.seminhematol.2013.06.007
   PubMed Web of Science ®Google Scholar
• Kaspers G, Pieters R, Klumper E, De Waal F, Veerman A. Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma. 1994;13(3–4):187–201. doi:10.3109/10428199409056282
   PubMed Web of Science ®Google Scholar
• Haarman EG, Kaspers GJL, Veerman AJ. Glucocorticoid resistance in childhood leukaemia: mechanisms and modulation. Br J Haematol. 2003;120(6):919–929. doi:10.1046/j.1365-2141.2003.04189.x
   PubMed Web of Science ®Google Scholar
• Goossens S, Van Vlierberghe P. Overcoming steroid resistance in T cell acute lymphoblastic leukemia. PLoS Med. 2016;13(12):e1002208. doi:10.1371/journal.pmed.1002208
   PubMed Web of Science ®Google Scholar
• Delgado-Martin C, Meyer LK, Huang BJ, et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017;31(12):2568–2576. doi:10.1038/leu.2017.136
   PubMed Web of Science ®Google Scholar
• Serafin V, Capuzzo G, Milani G, et al. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood. 2017;130(25):2750–2761. doi:10.1182/blood-2017-05-784603
   PubMed Web of Science ®Google Scholar
• Paugh SW, Bonten EJ, Savic D, et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet. 2015;47(6):607–614. doi:10.1038/ng.3283
   PubMed Web of Science ®Google Scholar
• Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;10(3):241. doi:10.1038/ni.1703
   PubMed Web of Science ®Google Scholar
• Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP 3 inflammasome activation and assembly. Immunol Rev. 2015;265(1):35–52. doi:10.1111/imr.12286
   PubMed Web of Science ®Google Scholar
• Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–489. doi:10.1038/s41577-019-0165-0
   PubMed Web of Science ®Google Scholar
• Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397–411. doi:10.1038/nri3452
   PubMed Web of Science ®Google Scholar
• Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89–102. doi:10.1038/nri2691
   PubMed Web of Science ®Google Scholar
• Samir P, Kesavardhana S, Patmore DM, et al. DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome. Nature. 2019;573(7775):590–594. doi:10.1038/s41586-019-1551-2
   PubMed Web of Science ®Google Scholar
• Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268(5218):1766–1769. doi:10.1126/science.7792603
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang X, Cui W, et al. Visualization of caspase-3-like activity in cells using a genetically encoded fluorescent biosensor activated by protein cleavage. Nat Commun. 2013;4(1):2157. doi:10.1038/ncomms3157
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–255. doi:10.1038/nm.3806
   PubMed Web of Science ®Google Scholar
• Wannamaker W, Davies R, Namchuk M, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoy l)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321(2):509–516. doi:10.1124/jpet.106.111344
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009;187(1):61–70. doi:10.1083/jcb.200903124
   PubMed Web of Science ®Google Scholar
• Davis BK, Wen H, Ting JP-Y. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol. 2011;29(1):707–735. doi:10.1146/annurev-immunol-031210-101405
   PubMed Web of Science ®Google Scholar
• Menu P, Vince J. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol. 2011;166(1):1–15. doi:10.1111/j.1365-2249.2011.04440.x
   PubMed Web of Science ®Google Scholar
• Distelhorst C. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 2002;9(1):6–19. doi:10.1038/sj.cdd.4400969
   PubMed Web of Science ®Google Scholar
• Inaba H, Pui C-H. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096–1106. doi:10.1016/S1470-2045(10)70114-5
   PubMed Web of Science ®Google Scholar
• Paugh SW, Bonten EJ, Evans WE. Inflammasome-mediated glucocorticoid resistance: the receptor rheostat. Mol Cell Oncol. 2016;3(1):e1065947. doi:10.1080/23723556.2015.1065947
   PubMed Web of Science ®Google Scholar
• Autry RJ, Paugh SW, Carter R, et al. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020;1(3):329–344. doi:10.1038/s43018-020-0037-3
   PubMedGoogle Scholar
• Schwaid AG, Spencer KB. Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space. J Med Chem. 2021;64(1):101–122. doi:10.1021/acs.jmedchem.0c01307
   PubMed Web of Science ®Google Scholar
• Angosto-Bazarra D, Molina-López C, Peñín-Franch A, Hurtado-Navarro L, Pelegrín P. Techniques to study inflammasome activation and inhibition by small molecules. Molecules. 2021;26(6):1704. doi:10.3390/molecules26061704
   PubMed Web of Science ®Google Scholar
• Zito G, Buscetta M, Cimino M, et al. Cellular models and assays to study NLRP3 inflammasome biology. Int J Mol Sci. 2020;21(12):4294. doi:10.3390/ijms21124294
   PubMed Web of Science ®Google Scholar
• Nizami S, Millar V, Arunasalam K, et al. A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation. Sci Rep. 2021;11(1):15319. doi:10.1038/s41598-021-94850-w
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yaginuma K, Tsutsui H, et al. ASC is essential for LPS‐induced activation of procaspase‐1 independently of TLR‐associated signal adaptor molecules. Genes Cells. 2004;9(11):1055–1067. doi:10.1111/j.1365-2443.2004.00789.x
   PubMed Web of Science ®Google Scholar
• FDA approved drug products: Micronase (Discontinued). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017498. Accessed February 9, 2022.
   Google Scholar
• Sola D, Rossi L, Schianca GPC, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840–848. doi:10.5114/aoms.2015.53304
   PubMed Web of Science ®Google Scholar
• Stack JH, Beaumont K, Larsen PD, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol. 2005;175(4):2630–2634. doi:10.4049/jimmunol.175.4.2630
   PubMed Web of Science ®Google Scholar